-
- G D Long.
- Section on Hematology/Oncology, Comprehensive Cancer Center of Wake Forest University, Bowman Gray School of Medicine, Winston-Salem, NC 27157, USA.
- Curr Opin Oncol. 1997 May 1; 9 (3): 301-6.
AbstractRenal cell carcinoma remains a major challenge for urologic oncologists. Over the past year, progress has been made in understanding the molecular biology of this disease and in describing new prognostic factors for outcome following nephrectomy. Studies have better defined patients who might benefit from elective nephron-sparing procedures without increasing the risk of relapse. Combination immunotherapy with interleukin-2 (IL-2) and interferon-alpha appears to be more active than single agent therapy and may be most effective when combined with chemotherapy. No new active chemotherapeutic agents have been identified. Prospective randomized trials suggest that autologous tumor cell vaccines as currently used offer little therapeutic benefit.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..